Tag: pertuzumab
Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing...
Positive top-line data from a recently completed dose-escalation study of BDC-1001 in HER2-expressing solid tumors support the drug to advance into two Phase 2...
José Baselga, a Leading Cancer Researcher, Dies at 61
José Baselga, MD, Ph.D., an internationally renowned expert in the development of molecular targeted agents, the R&D chief at AstraZeneca, who had earlier been...
Daiichi Sankyo Accelerates BLA Submission for [Fam-] Trastuzumab Deruxtecan in HER2...
Earlier this week Daiichi Sankyo announced plans to accelerate filing of their Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA)...
Breakthrough Therapy Designation for DS-8201 Confirms the Potential to Offer Substantial...
The U.S. Food and Drug Administration (FDA) earlier today confirmed that it has granted Breakthrough Therapy designation to DS-8201, an investigational HER2-targeting antibody-drug conjugate...
Presurgery Combination of Trastuzumab Emtansine + Pertuzumab May Improve Outcomes of...
The I-SPY 2 TRIAL, a private-public partnership combining personalized medicine with a novel investigational design, is a neoadjuvant Phase II clinical trial screening agents in combination with...
XMT-1522 Demonstrates Potent Activity in Low HER2-Expressing Tumor Models
Preclinical data for XMT-1522, a novel HER2-targeting therapy based on Mersana Therapeutics' Dolaflexin platform, the company's most advanced Fleximer® proprietary immunoconjugate technology, demonstrates significant anti-cancer activity...
